Purchase this article with an account.
Luiz F. Teixeira, Carla D. Macedo, Virginia L. Torres, Camila H. Hashimoto, Juliana S. Soares, Clelia M. Erwenne; Outcomes Of 105 Eyes With Intraocular Retinoblastoma Treated With Systemic Chemotherapy And/or Local Therapy As First Treatment. Invest. Ophthalmol. Vis. Sci. 2012;53(14):1883.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the outcome of 105 eyes with intraocular retinoblastoma treated with conservative treatment
Retrospective review of 85 consecutive patients with intraocular retinoblastoma (34 unilateral cases and 51 bilateral cases).
A total of 105 eyes, 9 group A eyes (9%), 22 group B eyes (21%), 17 group C eyes (16%), 43 group D eyes (41%) and 14 group E eyes (13%) were treated.Systemic chemotherapy associated with local therapy was performed as first treatment in 97 eyes (92%). Periocular carboplatin injection (20mg/2ml) was used in 13 group D eyes (30%) and in 7 group E eyes (50%) associated with systemic chemotherapy.Disease progression was observed in 57%(n=60 eyes) during the first treatment period (B-32%, C-35%, D-81% and E-86%). Enucleation was performed in 28 eyes(27%).Recurrence appeared in18 eyes from 77 eyes initially saved, after a mean follow up of 7 months (range 4-12months). Seven eyes were enucleated.Considering all forms of conservative treatments and excluding EBRT the final eye salvage rate was respectively: 100%/100% for group A, 95%/95% for group B, 88%/82% for group C, 49%/40% for group D, 54%/54% for group D with periocular carboplatin and 21%/0% for group E.A total of 70 eyes (67%) were saved.
Conservative treatment for intraocular retinoblastoma using systemic chemotherapy associated with local therapy is very efficient for initial disease. Most of the enucleations (80%) were indicated during the first treatment period. Recurrence appears most in the first year of follow up.
This PDF is available to Subscribers Only